Importantly, combinatorial treatment with MALT1 inhibitors (e.g., MI-2 and safimaltib) and BTKis (e.g., IBN and PBN) produced potent anti-MCL activity in both IBN-R MCL cell lines and patient-derived xenograft (PDX) models. This evidence concerns the gene MALT1 and mantle cell lymphoma.